CU Logo University of Colorado Anschutz Medical Campus
Back to Results

GS-US-682-6769/GOG-3104/ENGOT-en26: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Primary Objective

The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

Is This Study For You?

Let's Get Started!

Description

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy.

Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study. https://clinicaltrials.gov/study/NCT06132958?term=GOG%203104&rank=1
Locations

Highlands Ranch Hospital
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Bradley Corr

Bradley Corr

Study ID

Protocol Number: 24-1498

More information available at ClinicalTrials.gov: NCT06486441

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers